Standard versus prolonged doripenem infusion for treatment of gram-negative infections

Annals of Pharmacotherapy

Volumn 47, Issue 7-8, 2013, Pages 999-1006

  Hsaiky, Lama ^a   Murray, Kyle P ^b   Kokoska, Lianne ^c   Desai, Neha ^d   Cha, Raymond ^e  

^a OAKWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b Huron Valley Sinai Hospital   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

^d Oakwood Hospital   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; COLISTIN; DORIPENEM; QUINOLONE DERIVATIVE;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONCURRENT INFECTION; CRITICALLY ILL PATIENT; DRUG INFUSION; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HEALTH CARE PLANNING; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PNEUMONIA; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RETROSPECTIVE STUDY; STANDARD; TREATMENT DURATION; UROGENITAL TRACT INFECTION;

AGED; CARBAPENEMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880067681     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1S032     Document Type: Article

References (26)

1. Mandell L. Doripenem: a new carbapenem in the treatment of nosocomial infection. Clin Infect Dis 2009;49(suppl 1):S1-3. doi: 10.1086/599809
2. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009;49:291-8. doi: 10.1086/600036
3. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53: 60-7. doi: 10.1093/cid/cir202
4. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8. doi: 10.3201/eid1710.110655
5. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000;39:185-201.
6. Ikawa K, Morikawa N, Uehara S, et al. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents 2009;33:276-9. doi: 10.1016/j.ijantimicag.2008.08.031
7. Keel RA, Kuti JL, Sahm DF, Nicolau DP. Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitals. Am J Health Syst Pharm 2011;68:1619-25. doi: 10.2146/ajhp100569
8. Kim A, Banevicius MA, Nicolau DP. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 2008;52:2497-502. doi: 10.1128/AAC.01252-07
9. Samtani MN, Flamm R, Kaniga K, Nandy P. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. Antimicrob Agents Chemother 2010;54:2360-4. doi: 10.1128/AAC.01843-09
10. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012;16:R218. doi: 10.1186/cc11862
11. Castella X, Gilabert J, Torner F, Torres C. Mortality prediction models in intensive care: Acute Physiology and Chronic Health Evaluation II and mortality prediction model compared. Crit Care Med 1991;19:191-7.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
13. Product information. Doribax (doripenem). Raritan, NJ: August 2012.
14. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12. doi: 10.1086/595011
15. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36:1089-96. doi: 10.1097/CCM.0b013e3181691b99
16. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillintazobactam program in a large community teaching hospital. Pharmacotherapy 2002;22:471-83.
17. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006;40:219-23. doi: 10.1345/aph.1G467
18. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63. doi: 10.1086/510590
19. Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008;24: 2113-26. doi: 10.1185/03007990802179255
20. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008;30:868-83. doi: 10.1016/j.clinthera.2008.04.019
21. Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009;53:3782-92. doi: 10.1128/AAC.00837-08
22. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and metaanalysis. Clin Infect Dis 2013;56:272-82. doi: 10.1093/cid/cis857
23. Badal R BS, Hoban D, Johnson A, et al. Comparison of in vitro activity of doripenem and imipenem against Pseudomonas aeruginosa using Etest-the 2007-2008 CASTLE Study (abstract C1-0190). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Infectious Diseases Society of America Meeting. October 25-28, 2008, Washington, DC.
24. Christiansen KJ, Ip M, Ker HB, et al. In vitro activity of doripenem and other carbapenems against contemporary gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study. Int J Antimicrob Agents 2010;36:501-6. doi: 10.1016/j.ijantimicag.2010.08.002
25. Kiratisin P, Chongthaleong A, Tan TY, et al. Comparative in vitro activity of carbapenems against major gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. Int J Antimicrob Agents 2012;39:311-6. doi: 10.1016/j.ijantimicag.2012.01.002
26. Leblebicioglu H, Cakir N, Celen M, Kurt H, Baris H, Laeuffer J. Comparative activity of carbapenem testing (the COMPACT study) in Turkey. BMC Infect Dis 2012;12:42. doi: 10.1186/1471-2334-12-42